A Phase III Multicenter Randomized Double-Blind Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple sclerosis (Operetta 2)

Brief description of study

The study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with Relapsing-Remitting Multiple sclerosis (RRMS) The purpose of this research is to compare the effects, good or bad, of the study drug ocrelizumab versus fingolimod. Fingolimod is a medicine used for the treatment of patients aged 10 years and older with RRMS. Ocrelizumab is an experimental drug for children and adolescents.

Clinical Study Identifier: s21-00603
ClinicalTrials.gov Identifier: NCT04853251
Principal Investigator: Lauren B. Krupp.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.